SE468715B - Salt bildat mellan ranitidin och ett komplex av vismut med en karboxylsyra, foerfarande foer framstaellning av detta och en farmaceutisk komposition - Google Patents

Salt bildat mellan ranitidin och ett komplex av vismut med en karboxylsyra, foerfarande foer framstaellning av detta och en farmaceutisk komposition

Info

Publication number
SE468715B
SE468715B SE8902550A SE8902550A SE468715B SE 468715 B SE468715 B SE 468715B SE 8902550 A SE8902550 A SE 8902550A SE 8902550 A SE8902550 A SE 8902550A SE 468715 B SE468715 B SE 468715B
Authority
SE
Sweden
Prior art keywords
bismuth
methyl
salt
complex
ranitidine
Prior art date
Application number
SE8902550A
Other languages
English (en)
Swedish (sv)
Other versions
SE8902550L (sv
SE8902550D0 (sv
Inventor
J W Clitherow
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB888817098A external-priority patent/GB8817098D0/en
Priority claimed from GB898904686A external-priority patent/GB8904686D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of SE8902550D0 publication Critical patent/SE8902550D0/xx
Publication of SE8902550L publication Critical patent/SE8902550L/xx
Publication of SE468715B publication Critical patent/SE468715B/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
SE8902550A 1988-07-18 1989-07-17 Salt bildat mellan ranitidin och ett komplex av vismut med en karboxylsyra, foerfarande foer framstaellning av detta och en farmaceutisk komposition SE468715B (sv)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB888817098A GB8817098D0 (en) 1988-07-18 1988-07-18 Chemical compounds
GB898904686A GB8904686D0 (en) 1989-03-01 1989-03-01 Chemical compounds

Publications (3)

Publication Number Publication Date
SE8902550D0 SE8902550D0 (sv) 1989-07-17
SE8902550L SE8902550L (sv) 1990-01-19
SE468715B true SE468715B (sv) 1993-03-08

Family

ID=26294175

Family Applications (1)

Application Number Title Priority Date Filing Date
SE8902550A SE468715B (sv) 1988-07-18 1989-07-17 Salt bildat mellan ranitidin och ett komplex av vismut med en karboxylsyra, foerfarande foer framstaellning av detta och en farmaceutisk komposition

Country Status (35)

Country Link
US (1) US5008256A (no)
JP (1) JP2523185B2 (no)
KR (1) KR0122598B1 (no)
CN (1) CN1022626C (no)
AT (1) AT398200B (no)
AU (1) AU632052B2 (no)
BE (1) BE1003254A5 (no)
CA (1) CA1332610C (no)
CH (1) CH679582A5 (no)
CY (1) CY1650A (no)
DE (1) DE3923638C2 (no)
DK (1) DK168381B1 (no)
EG (1) EG19368A (no)
ES (1) ES2014175A6 (no)
FI (1) FI90538C (no)
FR (1) FR2634122B1 (no)
GB (1) GB2220937B (no)
GR (1) GR1000431B (no)
HK (1) HK61392A (no)
HU (2) HU206104B (no)
IE (1) IE61076B1 (no)
IL (1) IL91005A (no)
IT (1) IT1231481B (no)
LU (2) LU88722I2 (no)
MX (1) MX174145B (no)
MY (1) MY104055A (no)
NL (2) NL192604C (no)
NO (2) NO176319C (no)
NZ (1) NZ229958A (no)
PL (1) PL162391B1 (no)
PT (1) PT91188B (no)
SE (1) SE468715B (no)
SG (1) SG51992G (no)
YU (1) YU47021B (no)
ZW (1) ZW8689A1 (no)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85472A (en) * 1987-03-09 1991-06-30 Procter & Gamble Pharmaceutical compositions for treating gastrointestinal disorders
EP0282132B1 (en) * 1987-03-09 1992-09-30 The Procter & Gamble Company Compositions and their use for treating gastrointestinal disorders
AU641903B2 (en) * 1988-10-26 1993-10-07 Glaxo Group Limited Carboxylic acid derivatives
GB9004328D0 (en) * 1990-02-27 1990-04-25 Glaxo Group Ltd Chemical compounds
GB9009240D0 (en) * 1990-04-25 1990-06-20 Glaxo Group Ltd Chemical compounds
GB9009437D0 (en) * 1990-04-26 1990-06-20 Glaxo Group Ltd Chemical compounds
US5843482A (en) * 1990-07-20 1998-12-01 Tillotts Pharma Ag Products and processes for the treatment of the alimentary canal
GB9019875D0 (en) * 1990-09-11 1990-10-24 Glaxo Group Ltd Pharmaceutical compositions
US5192752A (en) * 1991-01-14 1993-03-09 The Procter & Gamble Company Swallowable pharmaceutical compositions containing colloidal bismuth subcitrate
US5128140A (en) * 1991-01-14 1992-07-07 The Procter & Gamble Company Swallowable pharmaceutical compositions
GB9120131D0 (en) * 1991-09-20 1991-11-06 Glaxo Group Ltd Medicaments
DE69228738D1 (de) * 1991-12-06 1999-04-29 Glaxo Group Ltd Zusammensetzungen zur Behandlung von entzündlichen Zuständen oder Analgesie, die Ranitidin Wismuth Citrat und einen NSAID enthalten
WO1996019232A1 (en) * 1994-12-19 1996-06-27 Lauteral Limited Combinations of ranitidine hydrochloride-form 1 and bismuth compounds
GB9501560D0 (en) 1995-01-26 1995-03-15 Nycomed Imaging As Contrast agents
US6117412A (en) * 1995-01-26 2000-09-12 Nycomed Imaging As Non-cluster type bismuth compounds
EP1035192A1 (de) * 1999-01-26 2000-09-13 Stefan Graichen Additiv für einen Kühlschmierstoff
CN1102585C (zh) * 1999-04-28 2003-03-05 常州兰陵制药有限公司 雷尼替丁枸橼酸铋盐的制备方法
US20060100271A1 (en) * 2004-11-08 2006-05-11 Keith Whitehead Stabilized aqueous ranitidine compositions
CN100402514C (zh) * 2006-08-01 2008-07-16 丽珠医药集团股份有限公司 一种制备枸橼酸铋雷尼替丁的方法
AU2007216671B2 (en) * 2007-07-09 2009-07-16 Cypress Pharmaceutical, Inc. Pleasant-tasting ranitidine formulation
CN102408398B (zh) * 2011-09-20 2012-12-05 江苏汉斯通药业有限公司 枸橼酸铋雷尼替丁的制备方法
US9731999B2 (en) 2011-09-23 2017-08-15 Iqbal Gill Chemical admixtures for hydraulic cements
ES2426539B1 (es) * 2012-04-18 2014-09-09 Dr Healthcare España, S. L. Uso de la diaminooxidasa para el tratamiento o la prevención del trastorno por deficit de atencion con hiperactividad (adhd)
CN103896888B (zh) * 2014-03-28 2015-11-18 常州兰陵制药有限公司 枸橼酸铋雷尼替丁的制备方法
WO2015155297A1 (en) 2014-04-11 2015-10-15 Sanovel Ilac Sanayi Ve Ticaret A.S. Pharmaceutical combinations of dabigatran and h2-receptor antagonists
EP2942058A1 (en) 2014-05-09 2015-11-11 Sanovel Ilac Sanayi ve Ticaret A.S. Pharmaceutical combinations of rivaroxaban and H2-receptor antagonists
CN107382921A (zh) * 2017-07-28 2017-11-24 常州兰陵制药有限公司 制备枸橼酸铋雷尼替丁的方法
EP4196793A1 (en) 2020-08-11 2023-06-21 Université de Strasbourg H2 blockers targeting liver macrophages for the prevention and treatment of liver disease and cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1565966A (en) * 1976-08-04 1980-04-23 Allen & Hanburys Ltd Aminoalkyl furan derivatives
FR2531706A1 (fr) * 1982-08-13 1984-02-17 Sanofi Sa Benzamides, leurs sels, procede pour leur preparation et compositions pharmaceutiques les renfermant
BE905235A (fr) * 1986-08-05 1986-12-01 Hasunor Ag Ascorbates antagonistes des recepteurs h2 et leur procede de preparation.
IT1215325B (it) * 1987-01-07 1990-02-08 Barisintex Sa Composti antagonisti di recettori -h2 e procedimento per la loro preparazione.
EP0282132B1 (en) * 1987-03-09 1992-09-30 The Procter & Gamble Company Compositions and their use for treating gastrointestinal disorders
IL85472A (en) * 1987-03-09 1991-06-30 Procter & Gamble Pharmaceutical compositions for treating gastrointestinal disorders
DE3710462A1 (de) * 1987-03-30 1988-10-13 Heumann Pharma Gmbh & Co Pharmazeutische zubereitung zur behandlung von erkrankungen des magen-darm-traktes
GB9004328D0 (en) * 1990-02-27 1990-04-25 Glaxo Group Ltd Chemical compounds
GB9009437D0 (en) * 1990-04-26 1990-06-20 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
KR910002826A (ko) 1991-02-26
JPH02117684A (ja) 1990-05-02
FI90538C (fi) 1994-02-25
CN1022626C (zh) 1993-11-03
CH679582A5 (no) 1992-03-13
MX174145B (es) 1994-04-25
LU87557A1 (fr) 1990-07-24
GB2220937B (en) 1991-11-27
NL192604B (nl) 1997-07-01
HUT52082A (en) 1990-06-28
FI90538B (fi) 1993-11-15
DK168381B1 (da) 1994-03-21
IT8948196A0 (it) 1989-07-17
NZ229958A (en) 1991-09-25
NO176319B (no) 1994-12-05
EG19368A (en) 1995-02-28
NO1998007I1 (no) 1998-02-05
CN1039419A (zh) 1990-02-07
IL91005A (en) 1994-10-07
AT398200B (de) 1994-10-25
NO176319C (no) 1995-03-15
SG51992G (en) 1992-07-24
DE3923638C2 (de) 1995-11-23
SE8902550L (sv) 1990-01-19
PL162391B1 (pl) 1993-10-30
NL192604C (nl) 1997-11-04
KR0122598B1 (ko) 1997-11-13
JP2523185B2 (ja) 1996-08-07
ES2014175A6 (es) 1990-06-16
NL970046I1 (nl) 1998-03-02
FI893448A0 (fi) 1989-07-17
AU3817889A (en) 1990-01-18
FR2634122B1 (fr) 1993-11-19
FR2634122A1 (fr) 1990-01-19
US5008256A (en) 1991-04-16
LU88722I2 (fr) 1996-08-23
NO892936D0 (no) 1989-07-17
GR890100454A (en) 1990-06-27
HK61392A (en) 1992-08-21
PT91188A (pt) 1990-02-08
ZW8689A1 (en) 1990-02-21
MY104055A (en) 1993-10-30
AU632052B2 (en) 1992-12-17
HU211173A9 (en) 1995-11-28
CA1332610C (en) 1994-10-18
BE1003254A5 (fr) 1992-02-11
NL970046I2 (nl) 1998-04-01
NL8901840A (nl) 1990-02-16
IE892309L (en) 1990-01-18
HU206104B (en) 1992-08-28
NO892936L (no) 1990-01-19
DK351789D0 (da) 1989-07-17
SE8902550D0 (sv) 1989-07-17
CY1650A (en) 1992-12-11
PT91188B (pt) 1995-03-01
DE3923638A1 (de) 1990-03-01
DK351789A (da) 1990-01-19
IE61076B1 (en) 1994-09-21
YU47021B (sh) 1994-11-15
GB8916288D0 (en) 1989-08-31
YU142789A (en) 1991-04-30
FI893448A (fi) 1990-01-19
GR1000431B (el) 1992-07-30
IT1231481B (it) 1991-12-07
MX16829A (es) 1993-10-01
IL91005A0 (en) 1990-02-09
GB2220937A (en) 1990-01-24
ATA172889A (de) 1994-02-15

Similar Documents

Publication Publication Date Title
SE468715B (sv) Salt bildat mellan ranitidin och ett komplex av vismut med en karboxylsyra, foerfarande foer framstaellning av detta och en farmaceutisk komposition
RU2007136430A (ru) Новые полиморфные формы рифаксимина, способы их получения и их применение в лекарственных препаратах
SE436874B (sv) N-substituerade moranolinderivat
JP2915021B2 (ja) カルボン酸誘導体
EP1341786B1 (de) Substituierte amino-furan-2-yl-essigsaure- und amino-thien-2-yl-essigsaure-derivate und ihre verwendung zur behandlung von migraine bzw. schmerz
DE60106421T2 (de) Hydrate und kristalle einer neuraminsäureverbindung
JPH05117259A (ja) カルボン酸誘導体
CH628346A5 (de) Verfahren zur herstellung neuer xanthinderivate.
RU2114857C1 (ru) Соли, образованные ранитидином и комплексным соединением висмута с карбоновой кислотой, и фармацевтический препарат
DE3222779C2 (no)
DE2559928C2 (de) N-Aroyl-L-phenylalanyl-L-tyrosine, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
SI8911427A (sl) Postopek za pripravo soli ranitidina z bizmutovimi kompleksi karboksilnih kislin
SU1299510A3 (ru) Способ получени производных хиназолинона
Billman et al. Hexahydropyrimidines I. Preparation of 2-substituted-1, 3-bis (p-dimethylaminobenzyl)-hexahydropyrimidines
JPH01121273A (ja) ベンズイミダゾール誘導体の多形体
DE2309135C2 (de) Cephalosporine und Verfahren zu deren Herstellung
SK279173B6 (sk) Komplexná soľ ranitidínu, spôsob jej výroby a farm
JPS6372691A (ja) 経口投与用セフアロスポリン水和物結晶
DD291554A5 (de) Verfahren zur herstellung von salzen eines furanderivates
BG61302B1 (bg) n-(3-(3-(1-пиперидинилметил)фенокси)пропил)хидроксиацетамид 1,2,3-пропентрикарбоксилат бисмут /3+/комплекс и метод за получаването му
CH484094A (de) Verfahren zur Herstellung von neuen Benzofuranderivaten und ihren Salzen

Legal Events

Date Code Title Description
NAL Patent in force

Ref document number: 8902550-6

Format of ref document f/p: F

NUG Patent has lapsed